Cantourage Group SEXTER:HIGH +3.64%22 EBITDA Margin % is 5.47% as of Jun. 2025. GuruFocus rates XTER:HIGH with a GF Score™ of 22/100. The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Cantourage Group SE ranks worse than 66.91% on this metric.
Cantourage Group SE (XTER:HIGH) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cantourage Group SE EBITDA Margin % Related Terms
Cantourage Group SE EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cantourage Group SE's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:HIGH vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cantourage Group SE's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantourage Group SE EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cantourage Group SE's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cantourage Group SE's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cantourage Group SE (XTER:HIGH) has a EBITDA Margin % of 5.47% as of Jun. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cantourage Group SE and its competitors. According to the industry distribution chart, Cantourage Group SE ranks #639 out of 955 companies in the Drug Manufacturers industry, placing it in the top 66.9%.
Is Cantourage Group SE's EBITDA Margin % too high?
Cantourage Group SE's current EBITDA Margin % is 5.47%. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Cantourage Group SE's value of 5.47% is 56% below this industry median. Based on the distribution chart, Cantourage Group SE ranks #639 out of 955 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cantourage Group SE has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Cantourage Group SE's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cantourage Group SE ranks #639 out of 955 companies for EBITDA Margin %. This places Cantourage Group SE in the lower half of its industry. The industry median EBITDA Margin % is 12.44. Cantourage Group SE's value of 5.47% is 56% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cantourage Group SE's current EBITDA Margin % of 5.47% is 56% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cantourage Group SE and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cantourage Group SE's current EBITDA Margin % is 5.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantourage Group SE stock overvalued right now?
Cantourage Group SE (XTER:HIGH) has a current EBITDA Margin % of 5.47%. The current EBITDA Margin % is 5.47% and 56% below the Drug Manufacturers industry median of 12.44. Cantourage Group SE's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cantourage Group SE (XTER:HIGH), the current EBITDA Margin % is 5.47% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantourage Group SE is engaged in the manufacture and wholesale of medicinal preparations based on cannabis and the trade and distribution of other legally permissible cannabis products, medical devices, pharmaceuticals, and accessories. The group offers cannabis flowers, dronabinol, CBD, and extracts of various strains.
22GF Score
Get the complete analysis for XTER:HIGH
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:HIGH has been successfully added to your 
